Gall Matthew has filed 6 insider transactions across 2 companies since March 2024.
Most recent transaction: a grant/award of 95000 shares of Kalaris Therapeutics, Inc. ($KLRS) on March 19, 2026.
Activity breakdown: 1 open-market purchase and 0 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 19, 2026 | Kalaris Therapeutics, Inc. | $KLRS | Gall Matthew | Chief Financial Officer | A | Stock Option (Right to Buy) | 95000 | $0.00 | 95,000.0000 | 18,702,418 | 9999.99% | 0.51% |
| Nov. 3, 2025 | Kalaris Therapeutics, Inc. | $KLRS | Gall Matthew | Chief Financial Officer | A | Stock Option (Right to Buy) | 235000 | $0.00 | 235,000.0000 | 5,043,357 | 9999.99% | 4.66% |
| March 7, 2025 | iTeos Therapeutics, Inc. | $ITOS | Gall Matthew | Chief Financial Officer | A | Common Stock | 24000 | $0.00 | 89,429.0000 | 38,194,341 | 36.68% | 0.06% |
| March 7, 2025 | iTeos Therapeutics, Inc. | $ITOS | Gall Matthew | Chief Financial Officer | A | Stock Option (Right to Buy) | 145000 | $0.00 | 145,000.0000 | 38,194,341 | 9999.99% | 0.38% |
| Nov. 19, 2024 | iTeos Therapeutics, Inc. | $ITOS | Gall Matthew | Chief Financial Officer | P | Common Stock | 5000 | $7.73 | 65,429.0000 | 0 | 8.27% | 0.00% |
| March 7, 2024 | iTeos Therapeutics, Inc. | $ITOS | Gall Matthew | Chief Financial Officer | A | Stock Option (Right to Buy) | 163200 | $0.00 | 163,200.0000 | 0 | 9999.99% | 0.00% |